HARTREE-PARTNERS
7.3.2024 08:01:28 CET | Business Wire | Press release
Hartree Partners (UK) Limited (“Hartree”), a wholly owned subsidiary of Hartree Partners LP, which is co-owned by its partners and funds managed by Oaktree Capital Management, announced that it has signed an acquisition agreement for a 50% share in Botres Holding GmbH and its subsidiaries (“Botres”). Headquartered in Graz, Austria, Botres is a key supplier of ultra-modern industrial biogas plants and biorefineries in Austria, Czech Republic, Poland, Italy, Spain and Turkey. Through Bio Scraper, its highly efficient biowaste treatment system, Botres covers the entire processing chain from pre-treatment of all types of organic waste to the efficient production of green energy.
Since being founded in 2012, Botres has built numerous biogas plants across Europe and Turkey and serves some of the world’s largest waste management and infrastructure companies. Botres is led by its founders Dr. Stefan Kromus and Dr. Markus Grasmug, who serve as Managing Directors. Jointly, Dr. Kromus and Dr. Grasmug have over 40 years of experience in the design, development, construction, and operation of waste focused biomethane plants.
Hartree is partnering with Botres to develop a European biomethane production business with a focus on Renewable Energy Directive (RED) compliant feedstocks, which will operate under the Botres brand. The business will focus asset development activities in select countries within the EU and will expand into additional countries on an opportunity-led basis.
“We are excited to partner with Botres, whose innovative technology and proven track record in the biogas space make them an excellent partner for our team as we enter the European biomethane production market. This collaboration directly aligns with Hartree's transition to investing in renewable energy solutions and we look forward to playing a role in providing Europe with clean and reliable biomethane,” said Stephen Hendel, Founding Managing Partner of Hartree Partners LP.
Dr. Kromus said, “We are thrilled to embark on this new chapter with Hartree Partners. This partnership presents a significant opportunity to accelerate the growth of our biomethane production business and solidify Botres' position as a leading player in the industry. We are confident that by combining our expertise and resources, we can deliver exceptional results for our stakeholders and contribute meaningfully to Europe's transition towards a more sustainable energy future.”
About Hartree:
Hartree Partners (UK) Limited is a wholly owned subsidiary of Hartree Partners, LP a limited partnership organised under the laws of Delaware and is a global commodities firm actively trading in oil, gas, power, refined products, shipping, metals and equities. Hartree Partners, LP was established more than 25 years ago and is jointly owned by senior management and funds managed by Oaktree.
Hartree has a unique 25+ year track record in proprietary trading and investing in energy markets across the globe. Our asset development experience ranges from VLCCs, oil, gas and power storage, power generation (conventional & renewable), and gas production facilities, as well as oil refining assets in the US. In Europe Hartree is involved in the UK power market through a portfolio of peak power assets, as well as a portfolio of pan-European renewable generation assets. Hartree acquired a deep knowledge base in the operation of these assets through extensive data analytics and has a wealth of experience in structuring transactions for renewable power and managing intermittent load.
About Botres:
Botres Holding/Botres Global GmbH, headquartered in Graz, Austria, is a leading supplier of modern industrial-scale anaerobic digestion biogas technology, covering the entire process chain from pre-treatment of all types of organic waste, manure and other residues to the efficient production of green energy. Botres was founded in 2012 and emerged from technology development at one of the world’s largest and most successful anaerobic digestion plants in Italy.
Over the past years, Botres has built numerous biogas plants in various European countries, Turkey and Australia. Among Botres’ customers are some of the largest waste management and infrastructure companies in the world. With the development of its highly efficient biowaste treatment system (Bio Scraper), Botres is able to treat basically any type of organic waste. In addition, the technological design and process stability of the plants ensure optimized life cycle expenditures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306806400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom